Praxis: connecting the neurological dots
Start-up’s neurology programs modulate channels in brain to normalize neuronal firing for epilepsies, mood and movement disorders
Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in funding, three clinical programs and a partnership with Ionis.
Incubated by Clarus Ventures in 2016, Praxis Precision Medicines Inc.’s initial focus was genetic epilepsy. The company has also received funding from Blackstone Life Sciences, Novo Holdings, Vida Ventures and Eventide.
The company was analyzing whole